Data from SKYSCRAPER-01 trial (NCT04294810) are awaited to assess tiragolumab, an anti-TIGIT antibody, with atezolizumab in first-line PD-L1 high NSCLC patients. The gene discussed is CD274; the disease is non-small cell lung carcinoma.